Kleefeld, Felix
Heller, Sophie
Ingiliz, Patrick
Jessen, Heiko
Petersen, Anders
Kopp, Ute
Kraft, Antje
Hahn, Katrin
Article History
Received: 15 February 2018
Revised: 27 March 2018
Accepted: 26 April 2018
First Online: 21 May 2018
Compliance with ethical standards
: The study followed the ethical principles of the World Medical Association (Declaration of Helsinki) and was approved by the local ethical research committee (reference number: EA1/153/14).
: Felix Kleefeld reports no conflict of interest.Sophie Heller reports no conflict of interest.Patrick Ingiliz has received lecture or consultancy fees from AbbVie, BMS, Gilead, Janssen, and MSD.Heiko Jessen has received payment for study cost from Gilead Sciences GmbH; for Board membership from Gilead Sciences GmbH, Bioscientia-Institut für Medizinische Diagnostik GmbH, and ViiV Healthcare GmbH; for speaker activities from ViiV Healthcare GmbH, AbbVie Deutschland GmbH & Co. KG, Bristol-Myers Squib GmbH & Co KGaA, Gilead Sciences GmbH, Gilead Sciences Ltd.; and for travel/accommodation/meeting expenses from ViiV Healthcare GmbH, AbbVie Deutschland GmbH & Co. KG, Bristol-Myers Squib GmbH & Co KGaA, Gilead Sciences GmbH, Gilead Sciences Ltd.Anders Petersen reports no conflict of interest.Ute Kopp reports no conflict of interest.Antje Kraft reports no conflicts of interest.Katrin Hahn has received speaker honoraria or consultancy fees or refunding of conference travel costs from AbbVie, Alnylam, Astellas, CSL Behring, Gilead Sciences GmbH, Pfizer, and ViiV Healthcare GmbH.